Reverse seroconversion of hepatitis B virus (HBV) after allogeneic BMT is rare. We present a case of HBV reactivation late after allogeneic BMT which responded well to lamivudine therapy. A 35-year-old woman with CML received an allogeneic BMT. Before BMT, the patient had immunity to HBV, with serum antibodies against hepatitis B surface antigen (HBsAb), and the donor was completely negative for HBV. Four years after BMT, acute hepatitis occurred with a detectable level of HBV-DNA. Lamivudine rapidly reduced transaminase and bilirubin levels, and serum HBV-DNA decreased to negative. Retrospective analysis revealed that there had been a gradual decrease in serum HBsAb titers after BMT. Administration of lamivudine immediately after HBV replication may be more effective than vaccination of hepatitis B surface antigen-negative donors before BMT. Bone Marrow Transplantation (2002) 29, 361-363. DOI: 10.1038/sj/bmt/1703387 Keywords: allogeneic BMT; hepatitis B virus; lamivudine; immunosuppression It has been suggested that hepatitis B virus (HBV) in a dormant state may persist in the setting of BMT and this has been termed 'latent' infection. Reactivation of such a latent infection has been suspected in patients who had evidence of HBV immunity and who showed positive test results for hepatitis B surface antigen (HBsAg) with or without hepatitis after BMT. Lamivudine, a nucleotide analogue that specifically inhibits viral reverse transcriptase, while suppressing HBV replication, is now being used widely in patients with chronic hepatitis B.
It has been suggested that hepatitis B virus (HBV) in a dormant state may persist in the setting of BMT and this has been termed 'latent' infection. Reactivation of such a latent infection has been suspected in patients who had evidence of HBV immunity and who showed positive test results for hepatitis B surface antigen (HBsAg) with or without hepatitis after BMT. 1 Lamivudine, a nucleotide analogue that specifically inhibits viral reverse transcriptase, while suppressing HBV replication, is now being used widely in patients with chronic hepatitis B. 2 Lamivudine has also been administered to patients with HBV to prevent progression to fulminant hepatitis following BMT. 3, 4 We report a case of reverse seroconversion from a hepa- 
Case report
In June 1996, a 35-year-old woman with chronic myelogenous leukemia received a fully HLA-matched and minor ABO-mismatched (from A to AB) allogeneic BMT in the first chronic phase from an unrelated healthy donor. The conditioning regimen consisted of ranimustine, cyclophosphamide and total body irradiation. Cyclosporin A and short-term methotrexate were administered for prophylaxis of acute GVHD. Cyclosporin A had been changed to tacrolimus because of encephalopathy. Hematopoietic engraftment was achieved, and the patient was treated with oral tacrolimus for acute hepatic GVHD. During follow-up after discharge, serum transaminase levels remained stable, and tacrolimus administration was stopped 11 months after BMT. Chronic GVHD of the skin and oral cavity with lichen planus was mild, needed no additional prednisolone, and disappeared 12 months after BMT. Thereafter, there was no clinical evidence of chronic GVHD. Before BMT, serological examination showed that the donor was negative for HBsAg and HBsAb, and had normal liver function, while the patient was positive for anti-HBs and had antibodies to hepatitis B core antigen and was negative for antibodies against hepatitis B e antigen (HBeAb). Tests conducted at the Japan Red Cross Hokkaido Blood Center showed that all of the patient's blood donors after BMT were negative for HBV prior to donation.
Icteric hepatitis with a peak ALT level of 2575 IU/l suddenly became apparent 51 months after BMT and 40 months after immunosuppressive drugs had been withdrawn, respectively. At the time of acute hepatitis, the patient had no signs of chronic GVHD, and was receiving no immunosuppressive treatment. Examination of HBV markers at that time showed an HBsAg-positive and HBeAg-positive status and revealed a detectable level of HBV-DNA. Antibody to hepatitis C was negative. Reactivation of Epstein-Barr virus (EBV), cytomegalovirus (CMV) and herpes simplex virus (HSV) was not detected in the serum, which was negative for antibodies to HSV
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IgM, HSV IgG, CMV IgM, EBV early antigen IgG and EBV viral capsid antigen (VCA) IgM, and positive for antibodies to CMV IgG, EBV VCA IgG, EBV nuclear antigen IgG. Hepatosplenic ultrasound was performed and showed mild hepatomegaly without splenomegaly. Stored serum samples were checked for HBsAb, HBeAb, HBsAg, HBeAg, and HBV-DNA and showed a gradual decrease in HBsAb but no detectable HBV-DNA until at least 4 months before the onset of hepatitis (Table 1) .
Lamivudine (150 mg/day) was immediately commenced, and HBV-DNA was rapidly suppressed after about 3 weeks. Liver dysfunction normalized and HBsAb appeared 2 months and 4 months after the start of lamivudine treatment, respectively. Lamivudine was well tolerated without any hematological side-effects. After 8 months of treatment, lamivudine was discontinued, and the patient is now well, with normal results on liver-function testing 13 months after the onset of hepatitis.
Discussion
Sources of HBV infection after BMT include reactivation of a latent infection, reactivation of occult chronic HBV hepatitis with positive testing for HBsAg and new HBV infection from BM or blood donors. 1, 5, 6 The patient's clinical history and lack of evidence of HBV in BM and blood donors supports the conclusion that the HBV hepatitis in this patient occurred from a latent infection.
It has also been speculated that the loss of HBsAb, which can occur after BMT, indicates a loss of specific immunity and reconstitution of HBV-negative donor-derived immunity. 5, 6 In the present case, the time course of decreasing serum titers for HBsAb was clearly demonstrated using Table 1 Serological data of HBV immunity before and after the onset of acute interic hepatitis CLIA = chemiluminescent immunoassay; RIA = radioimmunoassay; TMA = transcription mediated amplification; LGE = log genome equivalents (3.7 10 copies/ml = 3.7 LGE/ml).
stored serum. The late onset of hepatitis in this patient means that the reactivation of latent HBV was due not only to immunosuppression, but also to reconstitution with donor-derived naive immunity against HBV. Although HBV reactivation usually appears at immune reconstitution after BMT, its occurrence 4 years after BMT in this case is extraordinarily uncommon. Interferon has been shown to achieve a rapid fall in HBV in chronic active hepatitis B, but it may exacerbate hepatic damage by enhancing the immune clearance process. 7 Moreover, interferons are known to have a strong immunoregulatory effect and may induce GVHD by enhancing expression of class I or II antigens after allogeneic BMT. 8, 9 Therefore, lamivudine is currently the standard treatment of HBV reactivation in immunocompromised hosts, having replaced high-dose interferons.
Since the incidence of reactivation of a latent HBV infection after allogeneic BMT appears to be rare, routine vaccination of all seronegative donors before BMT or vaccination of reverse seroconverted recipients after BMT to prevent transplant-induced reactivation of latent HBV infection, cannot be advocated. Administration of lamivudine early after reactivation of HBV may be the best way to prevent hepatitis in patients where the reactivation occurred very late after BMT. The clinical picture is quite different from an early reactivation after BMT, because early HBV hepatitis occurs during tapering of immunosuppression or after immunological recovery from GVHD. Since HBV infection is likely to relapse and the associated liver disease can progress to fulminant hepatitis after lamivudine is stopped, the timing for cessation of the drug should be considered after appearance of HBsAb, as in our case. On the other hand, it is well known that the administration of lamivudine for a long period produces a mutation of HBV and the duration of lamivudine therapy should therefore be as short as possible. The reason why loss of serum HBsAb occurred very early compared with other reports might be the higher dose of lamivudine (150 mg/day) used in this patient. 2, 10 Since progressive disappearance of protective serum antibodies against HBV may occur, careful immunological follow-up for HBV immunity is warranted, even for patients with HBsAb before or after allogeneic BMT. Seronegative donor vaccination before BMT combined with booster immunization of the recipient after successful graft can be considered.
